current and future pharmacy practice

In order to keep competitive, pharma firms and their partners must keep current with the latest developments in drug delivery.

Using directed integration of antibody genes by CRISPR/Cas9 and TALENs, the construction of large libraries in mammalian cells containing a single antibody gene/cell has been achieved. This accomplishment has enabled the construction of libraries containing millions of monoclonal, stable, cell lines displaying IgG-formatted antibodies on their surface, and from which novel, high-affinity binders can be isolated. This technology also allows for the selection of antibodies with improved biophysical properties from libraries of variants.

Incorporation of patient-focused drug design principles is increasingly becoming essential to ensure that a new drug is commercially successful and delivers the best patient outcomes. Often, patient factors and insights are not considered or discovered until the later phases of drug development when dose form, dose strength, and route of administration are already decided. There is tremendous potential benefit of equipping formulators and other scientists with patient insights earlier in the development process so that the drug product can be designed to address the specific needs of target patient populations.

With the increase and complexity of the global supply chain, both the pharmaceutical cold chain and temperature-controlled shipping for the food and beverage industry have seen substantial growth over the last few years. It is no coincidence that the food industry is now beginning to look to the pharmaceutical supply chain for guidance on best practices, as the need for stricter standardization and controls has emerged.